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Abstract
Background: Streptococcus agalactiae or group B Streptococcus (GBS) has been recognized as a lethal pathogen in
neonates worldwide. S. agalactiae infections also severely affect pregnant women and immunosuppressed adults
with substantial attributable morbidity and mortality. However, in Latin America, studies on the epidemiology and
behaviour of S. agalactiae infections remain limited.
Methods: To better understand the behaviour of S. agalactiae infections in our region, we conducted a
retrospective study to phenotypically describe S. agalactiae isolates collected in one of the largest hospitals in
Colombia at two time periods: 1994–2001 and 2004–2012. The isolates were identified by biochemical analysis and
tested for antimicrobial susceptibility.
Results: In 1994–2001 a total of 201 S. agalactiae isolates were found in urine 38.3%, vaginal exudates 27.8%, soft
tissue 12.9%, and blood 8.5%. Susceptibility to ampicillin or penicillin was 94% whereas resistance to erythromycin
and clindamycin were 2.8% and 5.2% respectively. In total 46 culture-positive cases of invasive infections were
reported, 11 (24%) in neonates and 35 (76%) in adults. In 2004–2012 a total of 671 isolates were found in urine
47.8%, vaginal exudates 32.6%, soft tissue 2.7% and blood 9%. Susceptibility rates to ampicillin and penicillin were
98% whereas resistance to erythromycin and clindamycin were 12.5% and 9.4%. A total of 95 severe infections were
reported: 12 (12.6%) were in neonates, 5 (5.3%) in children and 78 (82.1%) in adults. Over the 17-year study period
the averaged prevalence of invasive S. agalactiae isolates was 17.4%. The estimated incidence for neonatal
infections was 1.34 per 1000 livebirths (0.99 × 1000 livebirths for early- onset disease and 0.35 × 1000 livebirths for
late- onset disease) whereas for non-pregnant adults the estimated incidence was 0.75 × 1000 admissions.
Conclusions: A remarkable increase in bloodstream infections in immunosuppressed adults and a shift to early
neonatal S. agalactiae infections were seen over time. We also found an increase in S. agalactiae resistance to
erythromycin and clindamycin during the study period, and the emergence of penicillin-nonsusceptible isolates.
Our findings are consistent with the global trends described elsewhere, reinforcing the need for S. agalactiae
control measures in our region.
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Background
Streptococcus agalactiae (Group B Streptococcus, GBS)
is a colonizing bacterium in the gastrointestinal and gen-
itourinary tracts of healthy adults, particularly in women
[1-3]. Since 1970, S. agalactiae has been considered a
very significant cause of severe neonatal infections with
high morbidity and mortality. It also affects pregnant
women, non-pregnant adults with underlying conditions
and the elderly [4]. Maternal S. agalactiae colonization
has been associated with early-onset neonatal septicemia
(<7 days of age) and meningitis with mortality rates up
to 60% [5]. The highest rates of early neonatal infection
occur in premature and low-birth-weight infants due to
their immature immune systems. By contrast, late-onset
infections (>7 days of age) have been associated with S.
agalactiae virulence, although less lethal, these infections
are considered nosocomial and may lead to neurologic se-
quels in 30% of survivors [6,7]. After 1990, in developed
countries S. agalactiae screening and risk-based intrapar-
tum chemoprophylaxis significantly reduced mortality to
5% [8]. However twenty years later, regardless a change in
the epidemiology, S. agalactiae is still an important cause
of severe infections. Intrapartum chemoprophylaxis has
reduced the early-onset disease in neonates [9,10] whereas
the late-onset disease remains stable [10]. Recently, a
remarkable increase in S. agalactiae invasive infections
in immunocompromised adults and the elderly has been
observed. Worryingly, the estimated mortality attribut-
able to S. agalactiae severe infections in the elderly is
more than 50% [11,12]. Another raising concern is the
potential emergence of tolerance to penicillin [13], the
drug of choice for prophylaxis and therapy of S. agalactiae
infections, and the resistance to clindamycin and erythro-
mycin which are commonly used in patients with a history
of beta-lactams allergy [8].
Although the highest burden of S. agalactiae infections
has been reported in industrialized countries, S. agalactiae
maternal colonization and invasive infections have been
also seen in non-industrialized nations [14-17]. Neverthe-
less, studies on the characterization and epidemiology of
S. agalactiae are still limited in developing countries and
implementation of control strategies remains undefined
due to the lack of supporting studies [18]. Severe neonatal
infections and fatal cases caused by S. agalactiae have
been reported in Latin America [7], however the behav-
iour and trends of S. agalactiae in non-pregnant adults
are unknown and somehow underestimated [7]. To better
understand the behaviour of S. agalactiae infections in
our region, we have described the epidemiological, clinical
and microbiological characteristics of invasive and nonin-
vasive S. agalactiae isolates from patients admitted to a
tertiary care hospital in Colombia over a 17-year period.
We hypothesize that emerging trends in S. agalactiae epi-
demiology are similar to those from high income countries




This retrospective and cross-sectional study included
clinical and microbiological records from patients with
S. agalactiae isolates admitted in a tertiary care hospital at
two time periods. Our hospital is a university-affiliated in-
stitution serving a population of approximately 700,000 lo-
cated in Cali (western Colombia), the third most populous
city in the country. This national reference hospital has
capacity for 500 beds, 180 of them in intensive care unit
(ICU), it also has specialized units for transplantation,
cancer surgery and dialysis. The medical center and the
laboratory also offer a wide range of outpatient services
and community-level healthcare.
A first survey was conducted from 1994 to 2001. Infor-
mation of S. agalactiae isolates was collected from the la-
boratory records (MicroScan, Baxter Scientific software).
Invasive and noninvasive isolates were identified and clin-
ical data from invasive infections were captured from the
hospital’s patient files. Following the implementation of a
new laboratory system, a second study period started from
2004 to 2012 and microbiology and clinical data were ob-
tained as for the first survey (MicroScan LabPro software
program; WalkAway Baxter Scientific). During the transi-
tion between laboratory systems (2002–2003) microbiol-
ogy data were not available.
Isolates
S. agalactiae isolates were identified by conventional
methods based on hemolysis, colony morphology, catalase
reaction and biochemical tests (Microscan WalkAway,
Baxter Scientific), in some cases (<10%) bacterial identi-
fication was confirmed using the Vitek 2XL, bioMérieux
system. Antimicrobial susceptibility testing was routinely
performed using standard broth microdilution (Microscan
WalkAway, Baxter Scientific). The minimum inhibitory
concentration (MIC) was determined for penicillin, ampi-
cillin, clindamycin, erythromycin, tetracycline and vanco-
mycin. From 2004 to 2012, linezolid and levofloxacin were
also included for susceptibility testing. Interpretive stan-
dards published by the Clinical and Laboratory Standards
Institute (CLSI) were used to categorize the MICs as sus-
ceptible, intermediate, or resistant [19]. Microbiology la-
boratory was enrolled in periodical internal and external
quality control programs to assure accuracy.
An invasive isolate was defined as that obtained from
usually sterile body sites including blood, soft tissue (ab-
scesses, ulcers and wounds) cerebrospinal fluid and syn-
ovial, peritoneal or pleural specimens. Isolates from urine,
sputum and secretions were considered noninvasive. This
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work was approved by the Ethics Committee of the
Foundation Valle del Lili Hospital (Number 170–2012).
Statistical analysis
Demographic and clinical data from each patient with
severe infection were obtained from clinical records in a
data collection form. Live birth and adults admission fig-
ures were provided by the hospital statistics department.
Univariate and multivariate analysis were conducted using
Epi info version 7 (CDC). For comparison of clinical and
epidemiological variables Chi square and Fisher’s exact
test were used as appropriate. A p value <0.05 was consid-
ered significant.
Results
From 1994 to 2001 a total of 201 S. agalactiae isolates
were identified, 139 (69.2%) were from outpatient samples
and 62 (30.8%) from inpatients samples. There were 152
women and 49 men (ratio 3.1:1). Isolates were recovered
from urine 38.3%, vaginal exudates 27.8%, soft tissue
12.9%, blood 8.5%, genital male secretions 6%, sterile fluids
2% and other sources 4.5%.
The annual frequency of S. agalactiae is shown in
Figure 1. An increase in the total of isolates was observed
between 1996 and 1998, but no particular reasons for this
were identified. In this 8-year period, 22.9% were consid-
ered S. agalactiae invasive isolates ranging from 6 to 34%,
higher prevalence rates were observed between 1998 and
2000 with 65% of the total cases occurring in this period.
Six hundred and seventy one isolates were recovered
during the last 9-year period (2004 to 2012), 530 (79%)
from outpatient samples and 141 (21%) were from hos-
pitalized patients. From the total of 671 patients, 540
were females and 131 were males (ratio 4.1:1). Sites of
isolation included: urine 47.8%, vaginal exudates 32.6%,
soft tissue 2.7%, blood 9%, sterile fluids 2.5% genital
male secretions 1.3% and other sources 4.1%. There were
considerably more S. agalactiae isolates in the recent
years; the number of isolates increased from 82 in 2009
to 112 in 2010 (Figure 1). From 2004 to 2012, 14% S.
agalactiae isolates were classified as invasive isolates
ranging from 6.8% to 23.8%.
Incidence for neonatal infections for the 17-year
period was 1.34 per 1000 livebirths (95% CI: 0.85-2.0).
The incidence rate for early- onset infections was 0.99
per 1000 livebirths (95% CI 0.57-1.5 per 1000) and the
late- onset incidence was 0.35 per 1000 livebirths (95%
CI 0.16- 0.84). For non-pregnant adults, overall inci-
dence was 0.75 severe cases per 1000 admissions (95%
CI: 0.61- 0.89).
Invasive S. agalactiae infections
Noninvasive isolates were mainly recovered from out-
patient samples (84%) and invasive isolates obtained
from inpatient samples (63%). From 1994 to 2001 a total
of 46 cases of severe infections were reported, 11 (24%)
in neonates and 35 (76%) in adults. Invasive isolates
were recovered from soft tissue 25 (54.3%), blood 17
(37%) and sterile fluids 4 (8.7%) (Figure 2A). Seventeen
cases of bacteremia were observed: 11 (64.7%) were in
neonates (6 early- and 5 late-onset infections) and 6
(35.3%) in adults (Figure 2B). The estimated incidence
for S. agalactiae neonatal infections in this period was
1.7 per 1000 livebirths (95% CI 0.86-3.0). The incidence
rates for early and late-onset disease were 0.9 per 1000
livebirths (95% CI 0.35-2.0) and 0.79 × 1000 livebirths
(95% CI 0.26- 1.8) respectively. Overall mortality for ne-
onates was 36.4% (4/11), all deaths occurred in patients
with early-onset infections.
Soft tissue infections prevailed in non-pregnant adults
(71.4%, 25/35) only 28.6% (10/35) of the invasive isolates
were recovered from blood or sterile fluids. No in-hospital
deaths were reported in adults. The estimated incidence
for invasive infections in non-pregnant adults was 0.79 per
1000 admissions (95% CI 0.55-1.1).
Figure 1 Annual distribution of S. agalactiae isolates over the study period.
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For the second period S. agalactiae was recovered
from 95 cases of severe infections, 12 (12.6%) neonates,
5 (5.3%) children and 78 (82%) adults. Invasive isolates
were obtained from blood 57 (60%), soft tissue 18
(18.9%), sterile fluids 17 (17.9%) and 3 (3.2%) catheters
(Figure 2A). Fifty seven patients with bacteremia were
reported: 12 (21%) were in neonates (11 early- and one
late-onset infection), 5 (8.8%) in children and 40 (70.2%)
in adults (Figure 2B). Mortality rate for neonates was
lower than that for the first period (16.6%, 2/12), two neo-
nates died; one with an early-onset infection and one with
late-onset infection. Risk factors identified in early neo-
natal infections were chorioamnionitis (3 cases), gesta-
tional diabetes (1 case), prematurity (4 cases), hemolytic
disease of the newborn ABO (1 case) and maternal fever
(1 case). The only late onset infection was considered
nosocomial. In this study period, the estimated incidence
for S. agalactiae neonatal disease was 1.1 per 1000 live
births (95% CI 0.58-1.9), mostly early-onset infections
(1 per 1000 livebirths), and the incidence for late- onset
disease was 0.09 per 1000 livebirths (CI 95%: 0.002-0.5).
S. agalactiae invasive infections affected five children
ranging in age from 5 months to 7 seven years. All infants
had underlying conditions including hepatic disorders
(3/5), cancer (1/5) and major surgical procedures (1/5).
The estimated incidence for invasive infections in adults
was 0.73 per 1000 admissions (95% CI 0.57-0.90). Most
patients with invasive S. agalactiae infections (91%, 52/57)
had at least one chronic underlying condition such as:
metastatic cancer, diabetes or transplant history. Twenty
of the 57 patients (35%) had more than one underlying
condition or predisposing factor (Table 1). No predispos-
ing conditions were clearly identified in 5 cases: it was as-
sumed that in two patients S. agalactiae may spread from
Figure 2 S. agalactiae invasive isolates in the study population. A) S. agalactiae invasive infections distributed by site of isolation, 1994–2001
and 2004–2012. B) Distribution of S. agalactiae bloodstream infections, 1994–2001 and 2004–2012.
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the gastrointestinal tract to blood, one patient had an
abdominal trauma before S. agalactiae infection and one
patient had acute self-limited gastroenteritis before having
S. agalactiae bacteremia. The remaining 3 patients devel-
oped S. agalactiae bone infections, one patient had septic
arthritis and other patient suffered spondylodiscitis with
no other associated risk factor or condition. The third pa-
tient with bone infection had morbid obesity. In none of
the three patients could the primary site of dissemination
be identified, S. agalactiae was not found in other infec-
tion sites despite being isolated from blood.
S. agalactiae invasive infections had a similar behav-
iour in male and female patients. However, females had
two times higher percentage of cancer (38%) than male
(16.7%) by contrast liver disorders were more frequently
seen in male (4.8% women vs 8.3% men). Polymicrobial
infections were also more frequent in male (Table 1). In
non-pregnant adults, 34 bloodstream infections were
documented. Bacteremia was more prevalent in male
and the elderly particularly in those aged 60 or over,
clinical features of these cases are described in Table 1.
Interestingly, 7 (20.6%) patients had mixed bloodstream
infections. Other clinical syndromes associated with S.
agalactiae infections were abscesses and cellulitis 8.2%,
arthritis 5.5% and peritonitis 5.5%. In 13 cases (22.8%)
mixed infections were reported.
A total of 40 (70%) patients with invasive isolates were
admitted in ICU with complications mainly associated
to neurological disorders and respiratory distress. Overall
in-hospital mortality in non-pregnant adults was 19.2%
and 24.1% in patients with bloodstream infections, how-
ever, neither age nor bloodstream invasion of S. agalactiae
were significantly associated with fatality (p = 0.4 and
p =0.34 respectively).
Table 1 Clinical characteristics of S. agalactiae invasive infections in non-pregnant adults 2004 – 2012
Total Invasive infections
n = 57 n (%)
Female n = 21
n (%)
Male n = 36
n (%)
Bloodstream Infections
n = 34 n (%)
Female 21 (36.8) 12 (35.3)
Male 36 (63.2) 22 (64.7)
≥60 y.o 25 (43.9) 8 (38) 15 (42) 18 (53)
Mean 53 y. o. 55 y. o.
Range [17–82] [24–83]
In-hospital fatality 10 (17.5) 3 (14.3) 6 (16.7) 7 (20.6)
Polymicrobial infections 13 (22.8) 2 (9.5) 11 (31) 7 (20.6)
Bloodstream infections 34 (59.7) 12 (57.1) 22 (61.1)
Underlying conditions
Cancer 14 (24.6) 8 (38) 6 (16.7) 10 (29.4)
-Hematologic malignancies 7 (12.3) 4 (19) 3 (8.3) 5 (14.7)
Diabetes 16 (28) 6 (28.6) 10 (27.8) 7 (20.6)
Transplant 4 (7) - 2 (5.6) 1 (2.9)
Cirrhosis/liver disorder 4 (7) 1 (4.8) 3 (8.3) 3 (8.8)
Renal disorder 7 (12.3) 1 (4.8) 2 (5.6) 3 (8.8)
Lung disease 3 (5.3) 2 (9.5) 2 (5.6) 2 (5.9)
HIV 3 (5.3) - 3 (8.3) 1 (2.9)
Autoimmune disorder 3 (5.3) 1 (4.8) 1 (2.8) 3 (8.8)
Other 3 (5.3) 2 (9.5) 2 (5.6)* 2 (5.9)**
More than one underlying condition 20 (35) 6 (28.6) 14 (38.9) 13 (38.2)
Portal of entry
Primary bacteremia 14 (41.2)
Skin and soft tissue 8 (23.5)
Respiratory tract 7 (20.6)
Gastrointestinal tract 4 (11.8)
Urinary tract 1 (2.9)
y.o: years old.
*No underlying condition was identified in 5 cases.
**No underlying condition was identified in 2 bloodstream infections.
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Noninvasive infections
Over the study period a great number of isolates were
obtained from urine samples. A total of 398 isolates
from urine were recovered from 322 (81%) female and 76
(19%) male patients with a ratio 4.2:1. Semi-quantitative
bacteriuria was determined in 161 patients. The mean of
the counts was 75.750 ± 27.507 CFU/ml, with no statistical
difference between men and women (74.661± 28.245 CFU/ml
and 81.111 ± 23.260 CFU/ml respectively). However 54%
of the bacteriuria counts were <100.000 CFU/ml and 46%
were ≥100.000 CFU/ml. Only 3.1% of the infections were
polymicrobial and 96.9% were single-microorganism
infections.
Susceptibility
In 1994–2001 susceptibility rates to penicillin and ampi-
cillin were 94% (189/201) with MIC breakpoints ≤0.12
and ≤ 0.25 μg/ml respectively 6% (12/201) of S. agalactiae
isolates had a MIC in the 0.25 to 2 μg/ml range which is
considered at the upper range of expected susceptibility
[20]. Susceptibility rates to other antimicrobials were:
97.2% erythromycin, 94.8% clindamycin, 21.4% tetracyc-
line and 100% vancomycin.
From 2004 to 2012 susceptibility rates for both penicil-
lin and ampicillin were 98.6%. Higher MICs to penicillin
(≥0.25 μg/ml) or ampicillin (≥0.5 μg/ml) were observed
in 1.4% isolates Eight isolates showed MICs ≥ 2 μg/ml
for ampicillin, 3 of them were recovered from sterile
sites and the remaining five from genital secretions. Six
isolates exhibited decreased susceptibility to penicillin;
two were recovered from sterile sites. Penicillin non-
susceptible isolates showed MICs ≥2 μg/ml, three of
them with reduced susceptibility to ampicillin and the
other three were resistant to erythromycin or tetracyc-
line. In 2012, we found two S. agalactiae isolates showing
a substantially reduced susceptibility to penicillin with
MICs >8 μg/ml, one of them obtained from catheter, also
showed reduced susceptibility to ampicillin (MIC 4 μg/ml)
and resistance to erythromycin (MIC >4 μg/ml). The
remaining isolate recovered from urine showed decreased
susceptibility to linezolid (MIC 2 μg/ml). Unfortunately
these strains were not saved for further testing.
Susceptibility rates to erythromycin and clindamycin
were 87.5% and 90.6% respectively. A significant increase
in erythromycin resistance was observed over the two
study periods (2.8% in 1994–2001 vs 12.5% in 2004–
2012 p = 0.0001). A monitoring of the resistance over
2004 to 2012 revealed an increase in erythromycin resist-
ance since 2007 with the highest prevalence rates in 2008
and 2012 (Figure 3). Among the total isolates, 8.9% (60/
671) were only resistant to erythromycin, 2.4% (16/671) to
clindamycin and concurrent resistance to both clindamycin
and erythromycin was identified in 3.7% (25/671). 24.8% of
the erythromycin resistant isolates showed constitutive re-
sistance to macrolide-lincosamine-streptogramine (MLS).
Susceptibility to other antibiotics was: 97.5% levofloxacin,
100% linezolid, 11.6% tetracycline and 99.7% vancomycin.
Additionally 98.8% isolates had MICs <1 μg/ml for dap-
tomycin and rifampicin. No differences were observed
in the susceptibility profile of invasive and noninvasive
S. agalactiae only a slight decrease in the susceptibility
MICs to ampicillin was observed in invasive isolates
(p = 0.02) (Table 2).
Polymicrobial and recurrent infections
S. agalactiae was commonly isolated with other bacteria
and fungi. Invasive isolates of S. agalactiae were signifi-
cantly involved in polymicrobial infections when com-
pared to noninvasive isolates [13.7%, (13/95) vs 3.5% (20/
576) p = 0.0002]. In 13 polymicrobial invasive infections S.
agalactiae was concomitantly found with Escherichia coli
(4/13), Staphylococcus aureus 2/13, Klebsiella pneumoniae
1/13, Citrobacter freundii 1/13, Enterobacter aerogenes
1/13, Streptococcus viridans 1/13 and Candida albicans.
Figure 3 Erythromycin and clindamycin resistance in S. agalactiae isolates, 2004-2012. Erythromycin (ERI) resistance (dashed line) and
clindamycin (CLI) resistance (grey solid line) are shown by year of isolation. Concurrent resistance to both clindamycin and erythromycin is also
shown (dotted line with asterisk).
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In a total of 20 noninvasive infections and colonizations
S. agalactiae was recovered with Escherichia coli 4/20,
Staphylococcus aureus 5/20 and Candida albicans 5/20.
Polymicrobial infections were not associated with fatal-
ity (p = 0.45).
Recurrent isolation and/or colonization were recorded
in the second period of study. A total of 36 (5.4%) cases
with at least two documented infections or S. agalactiae
colonizations were seen through the 2004–2012 period.
One recurrent invasive infection was reported in a 67 y. o
male with prostate cancer who developed osteomyelitis
and epidural abscess and received a penicillin regimen. He
had a relapsed two years later with positive cultures; the
patient was treated with ceftriaxone.
Microbiology of S. agalactiae
A total of 497 isolates were biochemically character-
ized. The most common biotypes comprise strains
that were beta-hemolytic, resistant to bacitracin and
non-carbohydrate fermenters. Non-hemolysin producing
isolates emerged since 2008 and they were mostly recov-
ered from urine samples (71% of isolates from urine vs
29% from other samples, p = 0.0001). Interestingly a small
percentage of S. agalactiae isolates showed biochemical
profiles typically seen in animal strains [21]. Four isolates
(0.8%) were susceptible to bacitracin and 71 (9%) were
lactose fermenters.
Therapy
In our hospital the most common therapeutic regimen
administrated in neonatal infections was the ampicillin/
gentamicin combination; however, after a S. agalactiae
positive culture, penicillin or ampicillin treatment alone
was adopted. Vancomycin was mainly used to treat S.
agalactiae infections in adults (24.5%, 13/49) followed
by ceftriaxone (18.4%, 9/49) and penicillin (10.5%, 5/49).
A combination therapy was administrated in many cases
to cover concurrent bacterial infections or as prophylaxis
to prevent them. Effective control of the underlying
disease was also addressed. No bacteriological failure was
documented after receiving empiric or consolidate anti-
microbial regimen.
Discussion
The estimated burden of the S. agalactiae disease in low-
and medium-income countries remains to be determined.
A recent meta-analysis estimated the global incidence of
S. agalactiae neonatal infections to be 0.53 per 1000 live-
births with 9.6% mean case-fatality ratio [7], however few
studies from low income countries were included and only
one from Latin America. We have reported the incidence,
epidemiology and emerging trends of S. agalactiae in-
fections in our hospital over 17 years. Overall incidence
of neonatal infections was 1.34 per 1000 livebirths
which is 2.5 times higher than the estimated global inci-
dence and twice higher the incidence reported for the
Americas (0.67 per 1000 livebirths) [7]. Data reported
from Latin América are variable and fluctuate between
0.3-1.15 × 1000 livebirths, with mortality rates ranging
from 20 to 60% [5,9,22-27]. Neonatal incidence
reported here is lower than previous reports by Bajaras
et al. in Colombia [23] (neonatal incidence: 1.8 per 1000
livebirths) and similar to that reported from Brazil by
Miura et al. (1.15 per 1000 livebirths 95% CI: 0.7-1.9)
[24], possibly due to similar hospital characteristics. By
contrast, lower mean incidence of neonatal infections
has been reported by Sarubbi et al. in Argentina (0.9 per
1000 livebirths) [25], Guzmán et. al. in Chile (0.73 per
1000 livebirths) [9], Vaciloto et al. in Brazil [0.63 × 1000
livebirths (95% CI 0.13-1.85)] [26] and Solorzano in
Mexico [0.65 × 1000 livebirths (95% CI 0.38- 1.11)] [27].
In this study we have seen a decline in the S. agalactiae
neonatal incidence from 1.7 × 1000 livebirths in 1994–
2001 to 1.1 per 1000 livebirths (p = 0.29) in 2004–2012.
Early-onset disease remained stable whereas a substantial
decreased in late-onset disease was observed. However,
our data may represent even a higher incidence as it has
been suggested that a real S. agalactiae neonatal incidence
Table 2 Antimicrobial susceptibility profiles for invasive and noninvasive S agalactiae isolates
Antibiotic 1994-2001 S. agalactiae susceptibility (%) 2004-2012 S. agalactiae susceptibility (%)
Invasive Noninvasive Invasive Noninvasive
Ampicillin 100 98.3 95.4 99.1
Penicillin 100 97.5 96.3* 99
Clindamycin 93 94.5 90.7 91.4
Erythromycin 97.5 97 85.3 88.2
Levofloxacin - - 96.9 97.6
Tetracycline 21.4 8.1 9.4 11.9
Vancomycin 100 100 100 99.6
Linezolid - - 100 100
*p = 0.02.
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may be two or three times higher than that defined by
microbiological confirmation [28].
Averaged mortality caused by neonatal infections in
the 17-year period (26%) was also higher than the global
case fatality ratio (9.6%) [7], nevertheless in the last 9
years a reduction in the number of fatal cases from
36.3% to 16.6% was observed, probably due to the recog-
nition of the disease and early treatment. Similarly to
previous studies, most fatalities occurred in early-onset
infections and low-birth-weight infants [7].
Worldwide incidence of invasive infections in non-
pregnant adults is widely variable and influenced by the
population of individuals with predisposing factors. In
high income countries a 2–4 fold increase in S. agalac-
tiae severe infections has been recorded since 1990 [29].
Incidence of invasive infections in adults ranges from 3.4
to 7 × 100.000 in US, and from 0.3 to 0.96 × 1000 ad-
missions in Europe [30]. In our study the behaviour and
incidence of the S. agalactiae invasive in adults (0.75 ×
1000 admissions) seems to be similar to that reported in
high income countries. We observed that in 1994–2001
most of the bacteremias caused by S. agalactiae occurred
in neonates (11/17, 64.7%), whereas in 2004–2012 these
infections prevailed in adults (21.1% vs 70.1%, p = 0.002).
Interestingly, S. agalactiae also emerged in non-infant
children with predisposing conditions (0.75%). This situ-
ation is consistent with reports from other parts of the
world where S. agalactiae infections in adults account for
75% of S. agalactiae invasive disease [20] and cases in
non-infant children are rising [31].
Most S. agalactiae invasive infections and particularly
S. agalactiae bacteremia occurred in old aged patients
but in contrast with other studies [32,33] males were the
most affected. Skin and soft tissue were the main portals
of entry for S. agalactiae blood invasion; however in
most cases the source infections could not be identified.
The most prevalent risk factors identified in non-pregnant
adults with severe S. agalactiae infections were diabetes
and cancer, particularly cancer of the immune system.
Interestingly we reported three cases of S. agalactiae bone
infections, formerly considered unusual, in patients with
no obvious underlying conditions.
Worldwide, the overall in-hospital mortality for non-
pregnant adults ranges from 3 -47%. In our study severe
clinical consequences during the S. agalactiae infection
far exceed previous reports (70% here vs 19%) [4]. A
total of 19% patients with predisposing conditions and
concurrent S. agalactiae invasive infection died. These
findings are similar to those reported in Thailand, US and
Taiwan with mortality rates ranging from 14% to 19%
[12,33]. As for other studies, mortality in non-pregnant
adults over the two study periods had a substantial in-
crease (0% vs 19.2%, p = 0.01) whereas neonatal mortality
seems to decrease over time.
S. agalactiae isolates were consistently obtained from
urine, vaginal swabs, blood and soft tissues. Over the study
period a steady increase on the total of S agalactiae
isolates was recorded, particularly in noninvasive iso-
lates from urine (p = 0.02) supporting the emergence of
S. agalactiae in urinary tract infections in our region.
Similar to other studies, most urine isolates were ob-
tained from women and >50% of the counts were < 105
CFU/ml, this agrees with the suggestion that S. agalac-
tiae bacteruria should be interpreted by lowering the
commonly used cut off values of ≥105 CFU/ml [34].
A changing trend was also seen in S. agalactiae invasive
isolates. Soft tissue isolates declined over the last study
period (p < 0.0001). A substantial shift form subcutaneous
to bloodstream infections in non-pregnant adults was
observed (60%, p = 0.01), this was even higher than that
reported in similar studies (23-36%) [12].
Previous studies have found that important proportion of
S. agalactiae infections are nosocomial (22%-26% [33,35])
and polymicrobial (26%) [35]. Studies in non-pregnant
adults by Skoff and Chen-Mao found 6.3 and 8.9% of
polymicrobial bacteremia, S. aureus was the concurrent
bacteria in half cases [29,33]. Here we reported a lower
overall rate of polymicrobial infections (16.8%) however
the frequency of polymicrobial bacteremia in our popu-
lation was higher compared with other studies. It was
also seen that Enterobacteriaceae and other gram nega-
tive bacteria rather than S. aureus were co-cultured with
S agalactiae, we assume they have been co-transferred
from an endogenous source such as gastrointestinal or
urinary tract. Invasive isolates were significantly more
involved in polymicrobial infections.
It has been assumed that many problems regarding
diagnosis and detection persist in developing countries
leading to an underestimation of the S. agalactiae burden.
In this study we also described the biochemical character-
istics of S. agalactiae isolates in our region. The presence
of non-hemolysin or low-hemolysin producing isolates
may have diagnosis implications. One of the leading tests
for S. agalactiae identification is based on its hemolytic
properties and low-hemolysin producers may not be de-
tected unless differential media are used [36]. Non-
hemolysin producing isolates were frequently recovered
from urine samples and blood agar was used to verify
hemolysis in these isolates. Although this phenotype
may reflect an intrinsic characteristic of urine isolates in
this study, it is also possible that urine differential cul-
ture media may induce hemolysin inhibition; however,
this will need further investigation.
S agalactiae phenotypes from animal origin have been
previously identified in humans [37]. In a small percentage
of our isolates we identified phenotypic traits described in
bovine S. agalactiae isolates such as lactose fermentation,
lack of hemolysin and susceptibility to bacitracin [21].
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Furthermore, most S. agalactiae isolates with higher
MICs for penicillin were also lactose fermenters. How-
ever any association between animal and human S. aga-
lactiae isolates and resistance needs to be further
elucidated.
S. agalactiae has been universally susceptible to peni-
cillin and other beta lactams. One consequence of the
implementation of chemoprophylaxis in industrialized
countries is the increasing reports of S. agalactiae resist-
ance to macrolide-lincosamide-streptogramine antibiotics
and the emergence of penicillin-nonsusceptible isolates.
Although in many developing countries the S. agalactiae
prophylaxis is not widely used, macrolide and lincosamine
resistance is also rising. All over the world resistance to
erythromycin has been also attributed to therapy for other
microorganisms [38].
In high-income countries resistance rates to erythro-
mycin range from 3 to 54% and 1 to 43% for clindamycin
[39] whereas studies in South America show resistance
rates between 6 and 11% for erythromycin and around 5%
for clindamycin [40,41]. In this study S. agalactiae isolates
examined in 2004–2012 showed a significant increase in
erythromycin resistance compared to those in 1994–2001
(Figure 3) however the increase in clindamycin resistance
did not reach statistically significance. These resistance
rates were similar to that reported by Nakamura et. al.
[41]. Here, invasive and noninvasive isolates had similar
susceptibility profiles which agree with erythromycin rates
reported by Garland et al. [39], but contrast with studies
in Brazil showing higher resistance to erythromycin in col-
onizing isolates [42]. Although resistance mechanisms
were not determined in this study, we could identified that
24.6% of the erythromycin resistant isolates were also re-
sistant to clindamycin suggesting a MLS constitutive re-
sistance phenotype, this is somewhat lower than other
studies in South America and worldwide reporting up to
50% [39]. Resistance to tetracycline was a common feature
(up to 88%) as seen elsewhere (46–91%) [38,39,41,43].
Fluoroquinolone resistance may be also present in S.
agalactiae examined in this study as we found 7 isolates
with MIC >4 μg/ml for levofloxacin. Levofloxacin-
resistant isolates have been reported since 2010 in
Argentina [44] and Brazil [41].
So far, resistance to penicillin or ampicillin remains
to be defined by the CLSI, although controversial
[20], in vitro S. agalactiae penicillin nonsusceptibility
(MIC >0.25 μg/ml) has been documented since 1995
[13,45]. Studies by Kimura have shown that nonsus-
ceptible S. agalactiae (NSGBS) are mostly recovered
from nonsterile body sites, they also suggest screening for
NSGBS using ceftizoxime [13]. In our study, most S. aga-
lactiae isolates remained highly susceptible to penicillin
and ampicillin, however for first time in our region we
describe strains with presumptive reduced susceptibility
to ampicillin and penicillin (MICs > 2 μg/ml). Of these,
two strains exhibited MIC >8 μg/ml for penicillin
which is considered extremely rare. Half isolates with
MICs >2 μg/ml for penicillin showed resistance to erythro-
mycin, which agrees with observations by Kimura [46]
who found that NSGBS are significantly more resistance to
erythromycin than penicillin susceptible isolates. In this
work, we also found NSGBS in specimens from sterile sites
(3/9), possibly for an endogenous nonsterile source.
Longtin et. al. have shown that NSGBS can be in-
duced after long-term penicillin therapy. In the same
study higher MICs to penicillin were associated with
point mutations in specific penicillin binding proteins
such as PBP 1a, PBP 2a and PBP 2x [45]. Although the
development of resistance mechanisms in S. agalactiae
are still under study, it is possible that susceptible adult
population exposed to concomitant antibiotic penicillin
or beta lactams-based therapies may be at risk of har-
bouring penicillin-nonsusceptible S. agalactiae strains.
Nevertheless, penicillin remains as the choice for the
therapy of S. agalactiae infections. In this study vanco-
mycin and ceftriaxone were usually administrated to
cover other concurrent infections and complications in
immunocompromised patients. In severe infections pro-
longed therapy was implemented to fully eradicate the
pathogen and avoid persistence and recurrence. None of
the patients reported microbiological failure suggesting a
role for the immune system status and pathogen interac-
tions in cases with clinical adverse outcome.
One limitation of this study is that only isolates from
one medical centre were included, in addition NSGBS
could not be confirmed by molecular methods due to
the retrospective nature of the analysis. However, we
think that our findings may represent the epidemiology
in our region and the data may be compared with studies
in similar hospitals in other countries.
Conclusions
One of the goals for the millennium is to decrease the
mortality of children under 5 years old. In our country,
neonatal mortality represents 63% of the children fatal-
ities, 43% occurring in the first week of life [47], however
the impact of S. agalactiae on these figures is still un-
known. We have shown that S. agalactiae infections may
behave in a similar manner to those reported in high and
middle income countries. This study has revealed a high
incidence and lethality of early neonatal infections, emer-
gence of severe infections in non-pregnant adults and an
increase of bloodstream and urinary tract infections. All
these data together with the emergence of antimicrobial
resistance and tolerance, strongly support the implemen-
tation of prevention measures. We have also identified
non-infant children with underlying conditions as a popu-
lation at risk for invasive infections.
Crespo-Ortiz et al. BMC Infectious Diseases 2014, 14:428 Page 9 of 11
http://www.biomedcentral.com/1471-2334/14/428
The epidemiology of S. agalactiae varies geographically
and population at risk must be identified and monitored.
Routinely risk-based or S. agalactiae swab screening in
pregnant women, chemoprophylaxis and/or effective
vaccine strategies should be considered in high risk
population. Tertiary care hospitals in Latin America hav-
ing transplantation, dialysis, cancer units or immuno-
compromised patients should recognize S. agalactiae as
a severe cause of disease by monitoring and implement-
ing policies to improve routinely detection, susceptibil-
ity testing and control. In these settings susceptibility to
penicillin, clindamycin and erythromycin should be tested
particularly in immunosuppressed patients at high nosoco-
mial risk and/or those highly exposed to antibiotic therapy.
Penicillin-nonsusceptible strains or isolates with a MIC
range near the susceptibility breakpoint (>0.12 μg/ml)
should be confirmed and further investigated to exam-
ine the potential molecular mechanism involved.
S. agalactiae vaccination strategies might be an effective
approach to overcome S. agalactiae emergence and con-
tribute to reduce the burden of S. agalactiae infection in
the developing world. However, studies on serotype dis-
tribution, resistance mechanisms and virulence factors
urge to determine its applicability in our region.
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